Transcript
Hello and welcome. My name is Perry Cook. I'm part of the NYP system, and my topic is the use of EZH2 inhibitors in the treatment of patients with follicular lymphoma (FL).
As you know, the first EZH2 inhibitor has now been approved, a drug called Tazverik, tazemetostat.
It is approved for patients with primary diagnosis of epithelioid sarcoma, as well as the treatment of patients with relapsed FL. In FL the indication is for patients with EZH2 mutation who have failed at least 2 prior lines of therapy.
It is also approved for patients with FL with wild type EZH2 in whom no alternative better option appears to be available.
EZH2 is a methyl transferase involved with gene regulation and basic physiology of the FL cell.
EZH2 can be inhibited by Tazverik, and this is pertinent for patients with EZH2 gain-of-function mutations, which make for a more aggressive growth of FL cells.
It is also a key regulator in the basic physiology, so in the background, the unmutated EZH2 is also a valid target.
